PTC Therapeutics Inc., a biopharmaceutical company based in South Plainfield, announced Monday it has signed a lease at the Bristol-Myers Squibb Co. campus in Hopewell.
Under the agreement, PTC will have access to 185,000 square feet of space, including an existing biologics facility and supporting research and operations building.
PTC said it plans to further develop the biologics facility to support gene therapy production and foster innovation and employment in the community. In addition, PTC will move its research operations to a newly-renovated building on the same campus.
PTC said it is not moving its existing operational headquarters in South Plainfield, but plans to relocate and expand its global discovery and research operations to the campus in 2020.
“The Hopewell facility is a vital part of our strategy to develop best-in-class therapeutics for patients with high unmet medical need,” PTC CEO Stuart W. Peltz said. “Obtaining this facility allows PTC to execute on our plans of rapidly advancing our gene therapy pipeline. Access to best-in-class technology and highly qualified biologics operation specialists is key for PTC to meet our goal of becoming a leader in gene therapy.”
The campus encompasses more than 1 million square feet, which BMS said it is transitioning into a multitenant research and development campus.
